Pictet Asset Management (Switzerland)’s Beam Therapeutics BEAM Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$22.4M	Buy	702,277 +315,042	+81%	+$10.2M	0.03%	435
2023 Q1	$11.9M	Buy	387,235 +379,792	+5,103%	+$15M	0.01%	582
2022 Q4	$291K	Buy	7,443 +3,230	+77%	+$145K	﹤0.01%	1508
2022 Q3	$201K	Buy	+4,213	New	+$240K	﹤0.01%	1411
2022 Q2	–	Sell	-15,882	Closed	-$910K	–	1589
2022 Q1	$910K	Hold	15,882	–	–	﹤0.01%	1065
2021 Q4	$1.27M	Buy	15,882 +13,579	+590%	+$1.16M	﹤0.01%	1054
2021 Q3	$200K	Buy	+2,303	New	+$231K	﹤0.01%	1624

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BEAM Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Beam Therapeutics (BEAM) stake by 81% in Q2 2023, buying an estimated $10.2M and bringing the position to 702,277 shares worth $22.4M. The position accounts for 0.03% of the portfolio, ranked #435.

Pictet Asset Management (Switzerland) first reported a position in BEAM in Q3 2021 and has held it in 7 quarters since. 194 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

Pictet Asset Management (Switzerland) held 702,277 shares of Beam Therapeutics worth $22.4M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 315,042 Beam Therapeutics shares in Q2 2023, an estimated $10.2M.
Beam Therapeutics made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #435 holding.
Pictet Asset Management (Switzerland) first reported a position in Beam Therapeutics in Q3 2021 and has held it in 7 quarters since.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.